<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4941">
  <stage>Registered</stage>
  <submitdate>5/12/2014</submitdate>
  <approvaldate>5/12/2014</approvaldate>
  <nctid>NCT02313012</nctid>
  <trial_identification>
    <studytitle>Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors</studytitle>
    <scientifictitle>A Phase 1a Multicenter, Open-label Safety, Tolerability and Pharmacokinetic Study of CC-90003, a Selective Extracellular Signal-Regulated Kinase (ERK) Inhibitor, in Subjects With Locally-Advanced or Metastatic, Relapsed, or Refractory BRAF or RAS-Mutated Malignancies</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CC-90003-ST-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neoplasm Metastasis</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CC-90003

Experimental: Dose Level 1 CC-90003 - CC-90003 by mouth (PO) daily on days 1 -21 of every 28 day cycle; Cycle 1, Days 1 to 28 will constitute the dose limiting toxicity (DLT) assessment period for purposes of non-tolerated dose (NTD) and Maximum Tolerated Dose determination.


Treatment: drugs: CC-90003
CC-90003 PO once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Summary of the adverse events (type, severity, and incidence) related to CC- - An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values regardless of etiology.</outcome>
      <timepoint>Up to 36 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Dose Limiting Toxicities of CC-90003 - Number of participants with dose limiting toxicities during the Dose Escalation Phase</outcome>
      <timepoint>Up to 18 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Maximum Tolerated Dose (MTD) of CC-90003 - The MTD is defined as the highest dose level at which no more than 1 in 6 participants experiences a dose- limiting toxicity (DLT) during the first 28 day cycle of treatment</outcome>
      <timepoint>Up to 36 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics (PK) observed maximum concentration (Cmax) - The maximally observed plasma concentration of CC-90003 (Cmax)</outcome>
      <timepoint>Cycle 1, Day 1, 2, 3 (predose), 8, 11 (predose), 15, 16, , Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>PK-Area under the plasma concentration time curve (AUC) - Area under the plasma concentration -time curve of CC-90003</outcome>
      <timepoint>Cycle 1, Day 1, 2, 3, (predose) 8, 11 (predose), 15, 16, Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>PK-Time to maximal plasma concentration (Tmax) - The time to reach Cmax</outcome>
      <timepoint>Cycle 1, Day 1, 2, 3 (predose) 8, 11 (predose), 15, 16, Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>PK- terminal half-life; t1/2 - Terminal phase elimination half-life (t1/2) is calculated as follows: t1/2 =ln(2)/?z, where ?z is the first order rate constant associated with the terminal portion of the CC-90003 plasma concentration curve</outcome>
      <timepoint>Cycle 1, Day 1, 2, 3 (predose) 8, 11 (predose), 15, 16, Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>PK-Apparent total body clearance (CL/F) - The apparent total body clearance of CC-90003 from plasma</outcome>
      <timepoint>Cycle 1, Day 1, 2, 3 (predose) 8, 11 (predose) 15, 16, , Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>PK- Apparent Total Volume of Distribution (Vz/F) - PK- Apparent Total Volume of Distribution (Vz/F) During the terminal phase for CC- 90003</outcome>
      <timepoint>Cycle 1, Day 1, 2, 3 (predose) 8, 11 (predose), 15,16, Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Accumulation index of CC-90003 - Accumulation represents the relationship between the dosing interval and the rate of elimination for the drug</outcome>
      <timepoint>Cycle 1, Day 1, 2, 3 (predose) 8, 11 (predose), 15, 16, Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Response Rate based on RECIST 1.1 - The proportion of subjects who achieve a best response of CR or PR.</outcome>
      <timepoint>Up to 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response - Duration of response is the time from the start of study treatment until the first documentation of an objective response (either CR or PR).</outcome>
      <timepoint>Up to 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Control - The proportion of subjects who achieve a best response of SD (documented at least 56 days after the start of study treatment) PR, or CR</outcome>
      <timepoint>Up to 36 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival - PFS is defined as the time from the start of study treatment until progression (PD) or patient death (any cause), whichever occurs first</outcome>
      <timepoint>Up to 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - Overall survival is defined as the time from start of study treatment until the date of death from any cause.</outcome>
      <timepoint>Up to 36 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Eligible study subjects in Part 1 and Part 2 must be 18 years or older

          2. Eligible study subjects must have histologic or cytologic confirmation of advanced,
             unresectable or metastatic solid tumors, and have at least one measurable lesion per
             Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

          3. Eligible study subjects must have Eastern Cooperative Oncology Group Performance
             Status (ECOG PS) of 0 or 1

          4. Eligible study subjects must exhibit acceptable liver, bone marrow, renal and cardiac
             functions as assessed by laboratory tests, ECG and ECHO or MUGA scan.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Subjects with symptomatic or unstable CNS metastases

          2. Subjects with a history of recent (within 28 days) systemic therapy for their
             underlying malignancy

          3. Subjects who have had surgery/radiotherapy within 2 weeks prior to start of study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>19</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <postcode>3002 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Celgene Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with
      locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be
      adequately tolerated with minimal side effects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02313012</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gordon Bray, MD</name>
      <address>Celgene</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>